Updated: Multiple Biosimilars To Avastin Have Launched In EU
Industry Had Expected June Roll-Out
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
You may also be interested in...
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.